Challenges in defining predictive markers for response to endocrine therapy in breast cancer

Future Oncology

Volumn 5, Issue 9, 2009, Pages 1415-1428

  Larionov, Alexey A ^a   Miller, William R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine therapy; Genetic signatures; Letrozole; Neoadjuvant; Predictive indices

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CD36 ANTIGEN; CYCLIN B1; CYCLIN D1; ESTROGEN RECEPTOR; GELATINASE A; INSULIN RECEPTOR SUBSTRATE 1; KI 67 ANTIGEN; LETROZOLE; MICRORNA; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN; HORMONE ANTAGONIST; TUMOR MARKER;

BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RNA EXTRACTION; RNA PROCESSING; TREATMENT DURATION; BREAST TUMOR; FEMALE; METABOLISM; NEOPLASM;

BREAST NEOPLASMS; FEMALE; HORMONE ANTAGONISTS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; TUMOR MARKERS, BIOLOGICAL;

EID: 74949101730     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.113     Document Type: Review

References (91)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2, 104-107 (1896).
2. Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631-643 (2009).
3. Miller WR, O'Neill J: The importance of local synthesis of estrogen within the breast. Steroids 50(4-6), 537-548 (1987).
4. Grodin JM, Siiteri PK, MacDonald PC: Source of estrogen production in postmenopausal women. J. Clin. Endocrinol. Metab. 36(2), 207-214 (1973).
5. Miller WR: Prediction of estrogen sensitivity/dependence. In: Estrogen and breast cancer. Miller WR (Ed.). R.G. Landes Co., TX, USA, 151-170 (1996).
6. Dixon JM: Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer. Expert Rev. Anticancer Ther. 8(3), 453-463 (2008).
7. Kaufmann M, von Minckwitz G, Bear HD et al.: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann. Oncol. 18(12), 1927-1934 (2007).
8. Ma CX, Ellis MJ: Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin. Oncol. 33(6), 650-656 (2006).
9. Murray J, Miller WR, Dixon JM: Neoadjuvant endocrine therapy models. Methods Mol. Med. 120, 489-502 (2006).
10. Macaskill EJ, Dixon JM: Neoadjuvant use of endocrine therapy in breast cancer. Breast J. 13(3), 243-250 (2007).
11. Miller WR, Larionov A, Renshaw L et al.: Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J. Clin. Oncol. 27(9), 1382-1387 (2009). ■■ Important study describing multigene signature predicting for neoadjuvant response to letrozole.
12. Miller WR, Larionov AA, Renshaw L et al.: Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet. Genomics 17(10), 813-826 (2007). ■ Paper reports genes changed after short-term treatment with letrozole. Separates tumors into four groups depending on their molecular response to letrozole.
13. Ellis MJ, Tao Y, Luo J et al.: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. 100(19), 1380-1388 (2008).
14. Dixon JM: The scientific value of preoperative studies and how they can be used. Breast Cancer Res. Treat. 87(Suppl. 1), S19-S26 (2004).
15. Iqbal S, Anderson TJ, Marson LP, Prescott RJ, Dixon JM, Miller WR: MIB-1 assessments in breast cancers. Breast 11(3), 252-256 (2002).
16. Dixon JM: Neoadjuvant therapy: surgical perspectives. In: Endocrine Therapy in Breast Cancer. Miller WR, Ingle JN (Eds). Marcel Dekker, NY, USA, 197-212 (2002).
17. Ma CX, Sanchez CG, Ellis MJ: Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 23(2), 133-142 (2009).
18. Dowsett M, Smith IE, Ebbs SR et al.: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res. 11(2 Pt 2), S951-S958 (2005).
19. Forouhi P, Walsh JS, Anderson TJ, Chetty U: Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br. J. Surg. 81(2), 223-225 (1994).
20. Kuerer HM, Newman LA, Smith TL et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17(2), 460-469 (1999).
21. Dixon JM, Love CD, Renshaw L et al.: Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr. Relat. Cancer 6(2), 227-230 (1999).
22. Sasano H, Suzuki T, Moriya T: Pathology of breast cancer following neoadjuvant therapy. In: Endocrine Therapy in Breast Cancer. Miller WR, Ingle JN (Eds). Marcel Dekker, NY, USA, 213-222 (2002).
23. Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR: Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br. J. Cancer 87(3), 334-338 (2002).
24. Miller WR, Dixon JM, MacFarlane L, Cameron D, Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur. J. Cancer 39(4), 462-468 (2003).
25. Miller WR, Dixon JM, Cameron DA, Anderson TJ: Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J. Steroid Biochem. Mol. Biol. 79(1-5), 103-107 (2001).
26. Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ: Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br. J. Cancer 94(7), 1051-1056 (2006).
27. Tao Y, Klause A, Vickers A, Bae K, Ellis M: Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J. Steroid Biochem. Mol. Biol. 95(1-5), 91-95 (2005).
28. Ellis MJ, Coop A, Singh B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. 19(18), 3808-3816 (2001).
29. Mackay A, Urruticoechea A, Dixon JM et al.: Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 9(3), R37 (2007). ■ Describes genes changed after short-term preoperative treatment with aromatase inhibitors. Relates changes to proliferative response.
30. Cappelletti V, Gariboldi M, De Cecco L et al.: Patterns and changes in gene expression following neo-adjuvant antiestrogen treatment in estrogen receptor-positive breast cancer. Endocr. Relat. Cancer 15(2), 439-449 (2008). ■ Interesting study reporting a multigene signature predictive for neoadjuvant response to tamoxifen. Additionally analyzes a small subset of paired biopsies to describe molecular changes caused by the treatment.
31. Dowsett M, Salter J, Hills M, Detre S, A'Hern R, Smith IE: Short-term presurgical treatment for all? Breast Cancer Res. 9(Suppl. 2), S13 (2007).
32. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22 (2007).
33. Miller WR, Anderson TJ, Iqbal S, Dixon JM: Neoadjuvant therapy: prediction of response. In: Endocrine Therapy in Breast Cancer. Miller WR, Ingle JN (Eds). Marcel Dekker, NY, USA, 223-229 (2002).
34. Elledge RM, Green S, Pugh R et al.: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int. J. Cancer 89(2), 111-117 (2000).
35. Ravdin PM, Green S, Dorr TM et al.: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 10(8), 1284-1291 (1992).
36. Dowsett M, Houghton J, Iden C et al.: Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17(5), 818-826 (2006).
37. Wright C, Nicholson S, Angus B et al.: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer 65(1), 118-121 (1992).
38. Lal P, Tan LK, Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am. J. Clin. Pathol. 123(4), 541-546 (2005).
39. Leyland-Jones BR, Ambrosone CB, Bartlett J et al.: Recommendations for collection and handling of specimens from group breast cancer clinical trials. J. Clin. Oncol. 26(34), 5638-5644 (2008).
40. Medeiros F, Rigl CT, Anderson GG, Becker SH, Halling KC: Tissue handling for genome-wide expression analysis: a review of the issues, evidence, and opportunities. Arch. Pathol. Lab. Med. 131(12), 1805-1816 (2007).
41. Koch I, Slotta-Huspenina J, Hollweck R et al.: Real-time quantitative RT-PCR shows variable, assay-dependent sensitivity to formalin fixation: implications for direct comparison of transcript levels in paraffin-embedded tissues. Diagn. Mol. Pathol. 15(3), 149-156 (2006).
42. Madabusi LV, Latham GJ, Andruss BF: RNA extraction for arrays. Methods Enzymol. 411, 1-14 (2006).
43. Hewitt SM, Lewis FA, Cao Y et al.: Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch. Pathol. Lab. Med. 132(12), 1929-1935 (2008).
44. Esposito G: Complementary techniques: laser capture microdissection - increasing specificity of gene expression profiling of cancer specimens. Adv. Exp. Med. Biol. 593, 54-65 (2007).
45. Jansen MP, Foekens JA, van Staveren IL et al.: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23(4), 732-740 (2005). ■ Interesting study that reports a gene-expression signature predicting for response to tamoxifen in advanced breast cancer.
46. Nygaard V, Holden M, Loland A, Langaas M, Myklebost O, Hovig E: Limitations of mRNA amplification from small-size cell samples. BMC Genomics 6, 147 (2005).
47. Nygaard V, Hovig E: Options available for profiling small samples: a review of sample amplification technology when combined with microarray profiling. Nucleic Acids Res. 34(3), 996-1014 (2006).
48. Zahringer H: Product survey: DNA/RNA isolation. Spoilt for choice. Lab Times 5, 50-58 (2007).
49. Ambion AB: mirVana™ miRNA Isolation Kit - Instruction Manual (2008).
50. Qiagen: miRNeasy Mini Handbook (2007).
51. Schroeder A, Mueller O, Stocker S et al.: The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7, 3 (2006).
52. Strand C, Enell J, Hedenfalk I, Ferno M: RNA quality in frozen breast cancer samples and the influence on gene expression analysis - a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol. Biol. 8, 38 (2007).
53. Egyhazi S, Bjohle J, Skoog L et al.: Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies. Clin. Chem. 50(5), 975-976 (2004).
54. Finke J, Fritzen R, Ternes P, Lange W, Dolken G: An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 14(3), 448-453 (1993).
55. Markoulatos P, Siafakas N, Moncany M: Multiplex polymerase chain reaction: a practical approach. J. Clin. Lab. Anal. 16(1), 47-51 (2002).
56. Brenan CJ, Roberts D, Hurley J: Nanoliter high-throughput PCR for DNA and RNA profiling. Methods Mol. Biol. 496, 161-174 (2009).
57. Chagovetz A, Blair S: Real-time DNA microarrays: reality check. Biochem. Soc. Trans. 37(Pt 2), 471-475 (2009).
58. Chiorino G, Mello Grand M, Scatolini M, Ostano P: From single gene to integrative molecular concept MAPS: pitfalls and potentials of microarray technology. J. Biol. Regul. Homeost. Agents 22(1), 7-16 (2008).
59. Wang Y, Barbacioru C, Hyland F et al.: Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 7, 59 (2006).
60. Branham WS, Melvin CD, Han T et al.: Elimination of laboratory ozone leads to a dramatic improvement in the reproducibility of microarray gene expression measurements. BMC Biotechnol. 7, 8 (2007). ■ Refreshing paper describing unexpected perspective for quality assurance in microarray studies.
61. Shi L, Reid LH, Jones WD et al.: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24(9), 1151-1161 (2006). ■ Report confirming that, despite some initial concerns, microarray technologies have reached the level sufficient for reliable assessment of gene expressions.
62. Arikawa E, Sun Y, Wang J et al.: Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics 9, 328 (2008).
63. Kubista M, Andrade JM, Bengtsson M et al.: The real-time polymerase chain reaction. Mol. Aspects Med. 27(2-3), 95-125 (2006).
64. Brentani RR, Carraro DM, Verjovski-Almeida S et al.: Gene expression arrays in cancer research: methods and applications. Crit. Rev. Oncol. Hematol. 54(2), 95-105 (2005).
65. Allison DB, Cui X, Page GP, Sabripour M: Microarray data analysis: from disarray to consolidation and consensus. Nat. Rev. Genet. 7(1), 55-65 (2006).
66. Sasik R, Woelk CH, Corbeil J: Microarray truths and consequences. J. Mol. Endocrinol. 33(1), 1-9 (2004).
67. Timlin JA: Scanning microarrays: current methods and future directions. Methods Enzymol. 411, 79-98 (2006).
68. Barbacioru CC, Wang Y, Canales RD et al.: Effect of various normalization methods on Applied Biosystems expression array system data. BMC Bioinformatics 7, 533 (2006).
69. Werner T: Bioinformatics applications for pathway analysis of microarray data. Curr. Opin. Biotechnol. 19(1), 50-54 (2008).
70. Rice TK, Schork NJ, Rao DC: Methods for handling multiple testing. Adv. Genet. 60, 293-308 (2008).
71. Simon R, Radmacher MD, Dobbin K, McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95(1), 14-18 (2003).
72. Ransohoff DF: Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4(4), 309-314 (2004).
73. Taylor JM, Ankerst DP, Andridge RR: Validation of biomarker-based risk prediction models. Clin. Cancer Res. 14(19), 5977-5983 (2008).
74. Molinaro AM, Simon R, Pfeiffer RM: Prediction error estimation: a comparison of resampling methods. Bioinformatics 21(15), 3301-3307 (2005).
75. Desmedt C, Ruiz-Garcia E, Andre F: Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur. J. Cancer 44(18), 2714-2720 (2008).
76. Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55(4), 623-631 (2009).
77. Lopez J, Percharde M, Coley HM, Webb A, Crook T: The context and potential of epigenetics in oncology. Br. J. Cancer 100(4), 571-577 (2009).
78. Tan DS, Reis-Filho JS: Comparative genomic hybridisation arrays: high-throughput tools to determine targeted therapy in breast cancer. Pathobiology 75(2), 63-74 (2008).
79. Tyson DR, Ornstein DK: Proteomics of cancer of hormone-dependent tissues. Adv. Exp. Med. Biol. 630, 133-147 (2008).
80. Voelkerding KV, Dames SA, Durtschi JD: Next-generation sequencing: from basic research to diagnostics. Clin. Chem. 55(4), 641-658 (2009).
81. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10(1), 57-63 (2009).
82. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26(5), 721-728 (2008).
83. Buyse M, Loi S, van't Veer L et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006).
84. Miller WR, Larionov A, Anderson TJ et al.: Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer 112(3 Suppl.), 689-694 (2008).
85. Kato K: Algorithm for in vitro diagnostic multivariate index assay. Breast Cancer 16(4), 248-251 (2009).
86. Simon R: Roadmap for developing and validating therapeutically relevant genomic classifiers. J. Clin. Oncol. 23(29), 7332-7341 (2005).
87. Berg AO, Armstrong K, Botkin J et al.: Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet. Med. 11(1), 66-73 (2009).
88. Ioannidis JP: Is molecular profiling ready for use in clinical decision making? Oncologist 12(3), 301-311 (2007).
89. Free software environment for statistical computing and graphics www.R-project.org
90. Open source and open development software project for analysis of genomic data www.bioconductor.org
91. Controlled vocabulary describing genes in terms of biological processes, molecular functions and cellular locations of their products www.geneontology.org